High-Dose Inactivated Influenza Vaccine Linked to Lower Rates of Hospitalization in HF
Patients with heart failure who receive a high-dose inactivated influenza vaccine have a decreased risk for hospitalization.
A study in Circulation: Heart Failure found that high-dose inactivated influenza vaccine (HD-IIV) is associated with reduced rates of hospitalizations related to laboratory-confirmed influenza, cardiorespiratory disease, cardiovascular (CV) disease, and heart failure (HF) in patients with HF.
These findings come from the DANFLU-2 trial, conducted in Denmark over three consecutive influenza seasons (2022-2023 to 2024-2025), which included individuals aged 65 years and older randomly assigned to receive HD-IIV or standard-dose inactivated influenza vaccine (SD-IIV).
The high-dose inactivated influenza vaccine is linked to lower hospitalization rates.
- Reduced rates of hospitalizations related to laboratory-confirmed influenza
- Lower rates of hospitalizations for cardiorespiratory disease, cardiovascular (CV) disease, and heart failure (HF)
Author's summary: High-dose influenza vaccine reduces hospitalization rates in heart failure patients.